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Abstract
Background: Glutathione S-transferase M1 (GSTM1) is thought to be involved in detoxifying several carcinogens and may
play a vital role in tumorigenesis. Numerous studies have evaluated the association between GSTM1 null/present
polymorphism and risk of prostate cancer (PCa). However, the results remain inconsistent. To derive a more precise
estimation, we performed a meta-analysis.
Methodology/Principal Findings: A comprehensive search was conducted to identify all eligible case-control studies. We
used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association. The overall association
was significant (OR= 1.28, 95% CI: 1.11–1.48, P= 0.001). Moreover, subgroup analyses showed GSTM1 null genotype
significantly associated with PCa risk among Asians (OR= 1.35, 95% CI: 1.03–1.78, P= 0.03) but not among Caucasians
(OR= 1.12, 95% CI: 0.96–1.31, P= 0.16). In addition, we did not find that smoking modified the genotype effect on the risk of
PCa.
Conclusions/Significance: The present meta-analysis suggested that GSTM1 null allele was a low-penetrant risk factor for
PCa among Asians.
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Introduction
Prostate cancer (PCa) is now thought to be one of the most
important medical problems in the male population [1]. In
European countries, it is recognized as the most common solid
neoplasm, with an incidence rate of 214 cases per 1000 men,
outnumbering lung and colorectal cancer [2]. Furthermore, PCa is
currently the second most common cause of cancer death in men
[3]. Genetic predisposition and environmental factors are likely to
contribute to the risk of PCa [4]; however, the etiology of PCa
remains unclear. PCa incidence rate varies remarkably in different
populations, highest among Africans, intermediate among Cau-
casians and lowest among Asians [5]. The variation in different
ethnicities suggests that the genetic and environmental factor may
play an important role in the etiology of PCa.
Generally, genetic susceptibility could modify the effect of
environmental exposure, possibly explaining the difference of PCa
incidence rate throughout the world. It is possible that the
susceptibility to PCa is determined by the interindividual
differences in the bioactivation of procarcinogens and detoxifica-
tion of carcinogens because of the polymorphisms in metabolic
genes. Glutathione S-transferase M1 (GSTM1) is thought to be
involved in detoxification of carcinogens, which has been
considered as a PCa susceptibility gene [6].
GSTM1, located on chromosome 1p13.3, detoxifies numerous
electrophilic substances, including carcinogens such as polycyclic
aromatic hydrocarbons, ethylene oxide, epoxides, and styrene.
GSTM1 expression could be hormonally controlled and induced
by phenobarbital or propythiouracil [7]. Three genetic poly-
morphisms, namely GSTM1*0 (GSTM1 null polymorphism),
GSTM1*A and GSTM1*B, have been identified. GSTM1*0 is
a deleted allele, and the homozygous allele (GSTM1 null
genotype) is thought to be associated with low ability to detoxify
several xenobiotics, reduced defense ability against oxidative stress,
and free radical-mediated cellular damage [8–10]. Many studies
on GSTM1 null genotype and PCa have compared the
homozygous deletion genotype with the genotypes containing at
least one functional allele (Null versus Present) [11–44]. Because
GSTM1 null genotype could affect PCa risk by mediating the
detoxification of activated tobacco carcinogens, it is with great
interest that the tobacco smoking might affect the association
between GSTM1 null genotype and PCa risk. Recent years,
several studies have evaluated this possible effect [11–44].
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However, the results are contradictory because of relatively small
sample size with low statistical power. We therefore conducted
a meta-analysis in order to provide an accurate estimate of the
association.
Methods
Identification and Eligibility of Studies
PubMed (1956 to July 2012) and Embase (1947 to July 2012)
database search was conducted using the following search terms:
‘‘GSTM1 or GST’’, ‘‘polymorphism or variant’’, and ‘‘prostate or
prostatic’’. Additional relevant studies were identified by a hand
search of the references of original studies. Of these studies with
the same or overlapping data, we selected the most recent ones
with the largest number of subjects. Studies included in this meta-
analysis should meet the following criteria: (a) evaluation the
association of GSTM null/present polymorphism and PCa risk
published in English language, (b) case-control study, (c) contain-
ing sufficient data for estimation of odds ratio (OR) with 95%
confidence interval (95% CI).
Data Extraction
Two authors independently extracted the data and reached
a consensus on all the items. For each study, the following
information was collected: first author, publishing year, ethnicity
of subjects, source of controls, number of cases and controls,
genotyping method. Different ethnic descents were categorized as
Caucasians, Asians, and Africans. If a study did not specify the
ethnicity or if it was not possible to separate participants according
to such phenotype, the group was termed ‘‘mixed ethnicity’’. For
study [21] including subjects of different ethnic populations, data
were collected separately whenever possible and recognized as an
independent study.
Statistical Analysis
The strength of the association between GSTM1 null/present
polymorphism and PCa risk was measured by ORs with 95% CIs.
The statistical significance of the summary OR was determined by
the Z-test. For GSTM1 null polymorphism, we estimated the risk
of the ‘‘Null’’ genotype on PCa risk, compared with the ‘‘Present’’
genotype. Stratified analyses were performed by ethnicities and
smoking status.
Heterogeneity was evaluated by x2-based Q-test. A P value of
greater than 0.10 indicates a lack of heterogeneity among studies
and the fixed-effects model was used to estimate the pooled OR of
each study (the Mantel-Haenszel method). Otherwise, the
random-effects model (the DerSimonian and Laird method) was
used [45,46]. Sensitivity analysis was performed to assess the
stability of results. Begg’s funnel plot and Egger’s test were
Figure 1. Flow chart of study selection based on the inclusion and exclusion criteria.
doi:10.1371/journal.pone.0046982.g001
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performed to assess the publication bias of literatures; P,0.05 was
considered statistically significant.
All statistical tests for this meta-analysis were performed with
STATA (version 10.0; Stata Corporation, College Station, TX).
Results
Eligible Studies
For PCa risk related to GSTM1 null polymorphism, articles
were retrieved based on the search criteria above. Study selection
process is shown in Figure 1. Ninety-five articles were retrieved.
However, there were obvious overlapping data among a number
of studies [23,34,39,42,47–51]. According to our inclusion criteria,
some of them were included [23,34,39,42,51]. Finally, a total of 36
studies including 6,202 cases and 8,209 controls were eligible for
the meta-analysis. Study characteristics are summarized in Table
S1. There were 7 studies on subjects of Asian, 17 of Caucasian, 3
of African and 9 of mixed ethnicity. Among them, 6 studies
evaluated the effect of smoking status on the association. The
controls from all eligible studies were frequency-matched controls
to cases by age and ethnicity. A classical PCR or multiple PCR
assay was conducted in 31 studies.
Meta-analysis
Overall, we found that GSTM1 null genotype was significantly
associated with increased risk of PCa (Null versus Present:
Figure 2. Forest plot of PCa risk associated with GSTM1 null polymorphism (for Null versus Present). The squares and horizontal lines
correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamonds represent the
summary OR and 95% CI.
doi:10.1371/journal.pone.0046982.g002
GSTM1 Null Genotype and Prostate Cancer
PLOS ONE | www.plosone.org 3 October 2012 | Volume 7 | Issue 10 | e46982
OR=1.28, 95% CI: 1.11–1.48, P=0.001; Table S2, Figure 2). In
addition, subgroup analyses showed that there was significant
association among Asians (Null versus Present: OR=1.35, 95%
CI: 1.03–1.78, P=0.03; Table S2, Figure 3), but neither in
Caucasians (Null versus Present: OR=1.12, 95% CI: 0.96–1.31,
P=0.16; Table S2, Figure 4) nor Africans (data not shown).
GSTM1-smoking Interaction
The data on GSTM1 null genotype stratified by smoking status
were available in six studies. Non-smokers with the GSTM1 null
genotype did not have a significantly increased PCa risk,
compared to Present genotype (Null versus Present: OR=1.25,
95% CI: 0.64–2.45, P=0.52; Table S2). In addition, there was no
significant association between GSTM1 null polymorphism and
PCa risk among smokers (Null versus Present: OR=1.16, 95% CI:
0.95–1.43, P=0.15; Table S2). This result was further confirmed
by logistic regression analyses (data not shown).
Test of Heterogeneity
The heterogeneity was reckoned between each of the studies
using Q-test. Overall significant heterogeneity was detected across
studies (Null versus Present: Pheterogeneity ,0.01; Table S2). In
stratified analysis by ethnicity, there was significant heterogeneity
among Asians (Pheterogeneity =0.01), Caucasians (Pheterogeneity ,0.01;
Table S2).
Sensitivity Analysis
In the sensitivity analysis, the influence of each study on the
pooled OR was examined by repeating the meta-analysis while
omitting each study, one at a time. This procedure confirmed the
stability of our overall result (data not shown).
Publication Bias
Begg’s funnel plot and Egger’s test were conducted to assess
a possible publication bias in the literature. The shapes of funnel
plots did not reveal any evidence of funnel plot asymmetry. The
results Egger’s test from showed no indication of publication bias
(P=0.08; Figure 5).
Discussion
We performed a systematic literature search and combined the
available results in the present meta-analysis, which is a useful
strategy for elucidating genetic factors in cancer [52]. GSTM1 is
thought to be involved in detoxification of hydrophobic electro-
philes or oxidized lipids derived from the metabolism of
xenobiotics [53,54]. The association of GSTM1 null polymor-
phism with different cancers, such as lung cancer [55], gastric
cancer [56], and bladder cancer [57], has been extensively
explored. The results of published studies on the association
between GSTM1 null polymorphism and PCa risk remain
conflicting and contradictory. The inconclusive results may be
due to a small effect of GSTM1 null polymorphism on PCa risk.
Figure 3. Forest plot of PCa risk associated with GSTM1 null polymorphism among Asians (for Null versus Present). The squares and
horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamonds
represent the summary OR and 95% CI.
doi:10.1371/journal.pone.0046982.g003
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The relatively low statistical power of published studies with small
sample size might be a reason as well. Mo et al [58] evaluated the
association between GSTM1 null polymorphism and PCa risk by
meta-analysis 3 years ago, but their study included overlapping
data which might cause the bias. In addition, their use of scales for
assessing quality or risk of bias is explicitly discouraged in
Figure 4. Forest plot of PCa risk associated with GSTM1 null polymorphism among Caucasians (for Null versus Present). The squares
and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The
diamonds represent the summary OR and 95% CI.
doi:10.1371/journal.pone.0046982.g004
Figure 5. Begg’s funnel plot for publication bias test [for Null versus Present]. Each point represents a separate study for the indicated
association. Log[or], natural logarithm of OR. Horizontal line, mean effect size.
doi:10.1371/journal.pone.0046982.g005
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Cochrane reviews [59]. Moreover, recently many original studies
have come out and provided a variety of results. Hence, we
conducted an updating meta-analysis to provide a quantitative
approach for combining all the available within same topic.
Concerning the reason methodology rules of meta-analysis
[60,61], our study might provide a more accurate estimation.
The present meta-analysis, including 6,202 cases and 8,209
controls, explored the association between GSTM1 null/present
polymorphism and PCa risk. Overall, we found that GSTM1 null
genotype was significantly associated with PCa risk. Moreover, the
association remained significant among Asians but not Caucasians.
GSTM1 is thought to be involved in detoxification of hydrophobic
electrophiles or oxidized lipids derived from the metabolism of
xenobiotics [53,54], and play a vital role in carcinogenesis. The
GSTM1 null genotype has no enzymatic activity and may affect
the detoxification of carcinogens. Thus, it might be capable to
alter the susceptibility to PCa among Asians. Given the important
biological roles, the significant association between GSTM1 null
polymorphism and PCa risk is reasonable and convincing.
In this study, we reported a significant association between
GSTM1 null polymorphism and PCa risk among Asians, but not
Caucasians. Ethnicity is a well established confounding factor for
PCa. Our result suggested a possible role of ethnic difference in
genetic backgrounds and the environment they lived in [62].
Actually, a number of studies have demonstrated that GSTM1
null genotype is significantly associated with some other cancers
only in Asians. Zhuo et al [63] found that GSTM1 null genotype
significantly increased susceptibility to oral cancer among Asians,
but not Caucasians. Wang et al [64] reported that the null
genotype of GSTM1 was a risk factor in cervical cancer among
Asians, but not Caucasians. A recent study by Wang et al [65]
showed that an increased hepatocellular carcinoma risk was
significantly affected by the null genotype of GSTM1 among
Asians. In addition, a meta-analysis by Qiu et al [66] provided
evidences that the GSTM1 null genotype is a low-penetrant risk
factor for gastric cancer development only in the Asian
population.
To date, there is no reasonable molecular mechanism to explain
the result. In the Caucasian population, the effect of the null
genotype of GSTM1 on PCa risk might be masked by the presence
of other as-yet unidentified causal genes involved in the de-
velopment of PCa. In addition, heterogeneous exposure patterns
to chemicals and environmental risk factors might also be taken
account into account for the difference. Because there was
relatively small sample size for African population, the result on
Africans should be interpreted with caution.
GSTMl is involved in detoxification of epoxides from carcino-
genic polycyclic aromatic hydrocarbons and combination of
exposure to cigarette smoking. Lack of GSTMl activity would
increase the burden with ultimate carcinogenic epoxides [33]. In
subgroup analyses by smoking status, the significant association
was neither detected among non-smokers nor smokers. This
suggested that smoking might not significantly modify the effect of
GSTM1 null polymorphism on PCa risk. However, the result on
undetected effect should be interpreted with caution because of
a relatively small sample size included in the study.
Several limitation of our study should be addressed. (i) Although
case misclassification bias was unlikely to exist in this study because
all PCa cases were confirmed on the basis of histological criteria,
we could not exclude the possibility that some control subjects had
latent PCa which had not been detectable by PSA analysis or
digital rectal examination (DRE). The undetected PCa in controls
might produce bias estimates toward the null, and the strength of
positive correlation might be underestimated. (ii) Our result was
based on unadjusted estimates because of the limited information
available. A more precise analysis should be conducted on the
basis of adjustment for confounders such as age. (iii) Data on
Africans was limited.
In summary, this meta-analysis provided the evidence that
GSTM1 null genotype might be a low-penetrant susceptibility
marker for PCa among Asians.
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